1. Home
  2. EFT vs RIGL Comparison

EFT vs RIGL Comparison

Compare EFT & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EFT
  • RIGL
  • Stock Information
  • Founded
  • EFT 2004
  • RIGL 1996
  • Country
  • EFT United States
  • RIGL United States
  • Employees
  • EFT N/A
  • RIGL N/A
  • Industry
  • EFT Finance Companies
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • EFT Finance
  • RIGL Health Care
  • Exchange
  • EFT Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • EFT 327.7M
  • RIGL 335.5M
  • IPO Year
  • EFT N/A
  • RIGL 2000
  • Fundamental
  • Price
  • EFT $12.08
  • RIGL $38.85
  • Analyst Decision
  • EFT
  • RIGL Buy
  • Analyst Count
  • EFT 0
  • RIGL 5
  • Target Price
  • EFT N/A
  • RIGL $38.20
  • AVG Volume (30 Days)
  • EFT 100.8K
  • RIGL 995.6K
  • Earning Date
  • EFT 01-01-0001
  • RIGL 08-05-2025
  • Dividend Yield
  • EFT 10.63%
  • RIGL N/A
  • EPS Growth
  • EFT N/A
  • RIGL N/A
  • EPS
  • EFT 1.73
  • RIGL 5.43
  • Revenue
  • EFT N/A
  • RIGL $267,921,000.00
  • Revenue This Year
  • EFT N/A
  • RIGL $59.93
  • Revenue Next Year
  • EFT N/A
  • RIGL N/A
  • P/E Ratio
  • EFT $7.62
  • RIGL $7.15
  • Revenue Growth
  • EFT N/A
  • RIGL 105.62
  • 52 Week Low
  • EFT $11.10
  • RIGL $12.66
  • 52 Week High
  • EFT $13.44
  • RIGL $43.72
  • Technical
  • Relative Strength Index (RSI)
  • EFT 43.69
  • RIGL 68.57
  • Support Level
  • EFT $12.00
  • RIGL $39.00
  • Resistance Level
  • EFT $12.24
  • RIGL $42.08
  • Average True Range (ATR)
  • EFT 0.08
  • RIGL 2.32
  • MACD
  • EFT 0.01
  • RIGL -0.37
  • Stochastic Oscillator
  • EFT 63.16
  • RIGL 53.26

About EFT Eaton Vance Floating Rate Income Trust of Beneficial Interest

Eaton Vance Floating-rate Income Trust is a closed-end management investment company. The company's objective is to provide a high level of current income and its secondary objective is capital appreciation.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: